Pfizer's New Breast Cancer Drug Shows Promising Results
The Hindu
Pfizer's experimental drug atirmociclib shows a 40% reduction in breast cancer progression, paving the way for new treatment opportunities. Discover more about its impact!
Pfizer's atirmociclib cuts breast cancer progression risk by 40%.
Combination therapy shows promise for tougher cases of breast cancer.
Over 90% of trial participants began treatment quickly.
Only 6.4% of patients stopped due to side effects.